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SUMMARY 
MicroRNAs (miRNAs) are small non-coding RNAs that can regulate gene expression by 
inducing either degradation or translational inhibition of a target mRNA. miRNAs have been 
indicated to regulate up to 90% of human genes and played significant role in heart diseases. 
Myocardial infarction (MI) is the most common cause of heart failure. Excessive 
production of reactive oxygen species (ROS) plays a key role in the pathogenesis of cardiac 
remodeling after MI. NADPH with Nox2 as the catalytic subunit is a major source for cardiac 
superoxide production. Nox2 expression is significantly increased in the infarcted area, 
especially in macrophages and myocytes. Mice lacking the Nox2 gene are protected from heart 
injury. 
Here we demonstrate to utilize the screening of the miRNA-targets using self-assembled 
cell (SAMcell) microarray to identify miRNAs that could regulate Nox2 expression and select 
three miRNAs, miR-106b, miR-148b, and miR-204, for further study. We use different in vitro 
assays to validate these miRNAs function on Nox2 expression and downstream products. After 
that we use acid-degradable polyketal particles that could effectively encapsulate miRNAs and 
deliver them into macrophages. Both in vitro and in vivo studies confirmed the PK3-miRNAs 
particles could inhibit Nox2 expression and activity, and significantly improve cardiac function. 
These results revealed new miRNAs for heart disease treatment and provided an effective 
strategy from miRNAs identify to in vivo delivery. 
Our study successfully combine the miRNAs high throughput screening system and 
macrophages specific delivery system and establish an easy and efficient method from screening 
 xiii 
to drug delivery. We validate this system and the selected miRNAs functions both in vitro and in 
vivo. This provides us new evidence and directions for not only myocardial infarction recovery, 





CHAPTER 1.  INTRODUCTION 
1.1 The Significance of Cardiovascular Disease and Research: 
Currently in the world, cardiovascular disease (CVD) is the major cause of death. Of 
those CVD related mortalities, deaths from heart attacks, which also be known as myocardial 
infarction (MI), contribute to the largest percentage. In 2013, more than half million 
Americans had a heart attack for the first time, while half of those had a recurrent attack; 
another 150,000 silent attacks went undiscovered, that means totaling about one attack every 
thirty-four seconds, while approximately one people would die because of a heart attack 
every minute[1]. 
Despite these appalling statistics, progresses in patient healthcare have raised the 
possibility to survive after an acute MI. However, structural responses of the heart during 
wound healing may lead to progressive heart failure. Cardiac remodeling, the host of 
structural changes, offers a new window of therapy. It aims at limiting these adverse 
remodeling events and improving patient outcomes of therapy. Therefore, extensive research 
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into the pivotal events and mediators of the cardiac remodeling process is in highly demand 
to exploit and improve current therapies. 
1.2 Ischemic Injury After Myocardial Infarction 
Myocardial infarction is a kind of ischemic disease. It’s usually followed by plaque or 
thrombus formation inside a coronary vessel. Consequently, the blood flow to the 
downstream myocardium will be disrupted[2] (Figure 1-1). The term “ischemia” means to 
“restrain blood” or “without blood.” Nowadays, investigators specifically define ischemia in 
the heart as an insufficient in the supplement of substrates and oxygen to meet the 
requirements in order to maintain normal function of myocardium[2][4][5]. Ischemia is 
different from “hypoxia”. There is a accumulation of metabolic wastes in ischemic area as a 
result of the limited blood flow, which does not happen during hypoxia. This will 
excessively contributes to ischemic damage[5]. Following MI, the shortage supplement of 
oxygenated blood to the ischemic area results in a fast decreases in oxygen level that 
available to the myocardium. This will reduce the oxidative phosphorylation rate by the 
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mitochondria of cardiac myocytes and consequently, ATP production. In order to preserve 
function, cardiac myocytes, which are essential contractile cell for the heart, depend mostly 
on a less efficient, but normal, anaerobic glycolysis to generate ATP. However, contractile 
disorders are unavoidable. Because the consumption of ATP stores will result in failure of 
Na+/K- ATPases, disturbed Ca2+ handling and eventually the loss of the homeostatic 
intracellular environment. Areas of reversible myocytes dysfunction will transit into a zone 
of irreversible ischemic damage without the restoration of oxygenated blood flow. This area 
is defined as the “infarct zone,” marked with cell death by necrosis, apoptosis and 
autophagy[6]. After this, infarct scar is developed to stabilize the necrotic region and prevent 
ventricular rupture, as the result of activation of the cardiac wound healing process. In severe 
cases of MI, maladaptive cardiac remodeling responses that keep the heart in a state of 










Figure 1-1: Schematic diagram of myocardial infarction. A, Occlusion of the left 
anterior descending artery (LAD) leads to a shortage supply of blood and substrates to 
the downstream myocardium known as myocardial “ischemia”. B, A mouse model of 
MI injury and repair has been developed which utilizes surgical ligation of the LAD 
artery to trigger a wave of necrosis in the downstream myocardium, refers to the 
infarct zone, leading to the formation of a infarct scar C, on the antero-apical wall of 
the left ventricle. 
Besides of the challenging techniques needed to induce MI, the progression and 
prognosis of post-MI remodeling is a complex disease to research because of a range of 
stimuli from different sources. Despite of this fact, a MI model has still been generated in 
different species including the monkey, pig, dog, cat, rabbit, rat, and mouse[10-13]. 
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Canonically, animal models of MI are produced via surgical induction of coronary artery 
occlusion. This is most commonly done with the left anterior descending (LAD) artery to 
block the flow of blood to the anterior wall and apex of the left ventricle (LV) (Figure 1-1). 
1.3 Inflammation 
Hearts are unable to regenerate functional myocytes, which might be the major 
complication to treat an MI. This also makes it incapable for hearts to be fully recovered 
from irreversible ischemic damage and vulnerable to heart failure. Consequently, the process 
becomes unavoidable that wound healing is quickly initiated to take place and enforce the 
ischemic regions via developing an infarct scar. During this process, cells from the 
inflammatory system work together with wound healing cells through chemical modulators, 
such as cytokines, inducing the activation and orchestration of the wound repairing process. 
Following MI, he transcription factor Nuclear Factor (NF) in resident cells will be 
activated by the necrosis in the infarcted region. This also triggers the production of 
chemokines (i.e. Monocyte Chemoattractant Protein (MCP)-1), cytokines (i.e. Tumor 
6 
Necrosis Factor (TNF), interleukin), and adhesion molecules[14-16]. These chemokines and 
cytokines induce related signaling pathways and establish a “pro-inflammatory” 
environment, marked by extensive degradation of extracellular matrix (ECM) via activation 
of matrix metalloproteases (MMPs), which are secreted by cardiac fibroblasts (CFs). There 
are also other kind of cells that targeted to the injury site, including the pro-inflammatory M1 
macrophages, mast cells, neutrophils, and lymphocytes. These cells will begin to clear of 
cellular debris in the infarcted area. Once finished, apoptosis of these recruited neutrophils 
activate expression of IL-10 and transforming growth factor (TGF) from macrophages. 
Consequently, the inflammatory processes will be repressed[17-18]. 
These inflammatory chemokines also initiate the proliferation of cardiac fibroblast and 
endothelial cell proliferation[17, 19]. During this process, cytokines such as TGF-β stimulate 
the transition from the pro-inflammatory M1 macrophage to the M2 macrophage.  This 
wound healing process helps in repair following MI and express enzymes important for 
ECM remodeling[18]. Moreover, TGF-β and other hormones, which commonly expressed in 
the tissue after MI such as angiotensin II (Ang II), also induce cardiac fibroblast 
 
 7 
differentiation and activation into myofibroblasts. This kind of cells secrete large amounts of 
collagen, mostly type I and type III, to preserve the infarcted area structural integrity and 
prevent ventricular rupture. This is fulfilled by form a new microvascular network via 
endothelial cells[20-21]. Following wound stabilization, a mature, densely arranged 
collagenous infarct scar is formed by fibroblasts apoptosis and inflammatory process 
maturation[16]. 
1.4 Cardiac Remodelling 
The cardiac remodeling is described as the geometrical changes happening in the LV of 
post-MI hearts, more specifically referring to dilation of the LV cavity[22]. Up to now, large 
amounts of studies have expanded the principle of cardiac remodeling. Now it is defined as a 
variety of clinical scenarios resulting into downstream different paths of pathological 
remodeling. However, all of these converge on one common outcome, ventricular 
dysfunction[23]. 
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The cardiac remodeling process post-MI is more complex compared to other CVDs. 
Because there are various types of inflammatory imposed to the myocardium, as well as 
biomechanical stress. These are not happened in other disease. The post-MI remodeling 
process is so complex that includes responses for infarct expansion, pressure overload, and 
subsequent raise in wall-stress. However, these responses eventually push the patient into 
serious dilated heart failure (Figure 1-2)[23-24]. Early compensatory cardiac hypertrophy, wall 
thinning and LV chamber dilation, infarct expansion, and tissue fibrosis are resulted from 
heart failure related geometrical changes. All of these could be visualized and quantified by 
in vivo imaging techniques such as echocardiography[25]. Typically, parameters, like 
interstitial collagen, volume of LV end-diastolic, area of myocyte cross-sectional, can be 











Figure 1-2: Model of pathological responses by the heart to MI injury. Following severe 
cases of MI, a series of temporal wound healing responses at the molecular, cellular and 
tissue level occur, leading to adverse cardiac remodeling events and results in dilated 
cardiomyopathy, cardiac fibrosis and eventual heart failure. 
Following MI, it’s in a higher functional demand on the remaining viable, non-infarcted 
myocardium to maintain enough cardiac function, due to heart myocytes lost in the infarcted 
areas. Hypertrophy is a compensatory response activated related to this increased mechanical 
demand. This will result into an increase in the amount of contractile units (sarcomeres) per 
cardiac myocyte and thickness of myocardial wall. These changes help heart to maintain 
cardiac function and normalize wall-stress (Law of Laplace), respectively[23-24]. Besides of 
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these physical factors, other various types of stimulations, including the hormones, growth 
factors such as insulin-like growth factor-1 (IGF-1), fibroblast growth factor (FGF) and 
cytokines like TGF-β also contribute to cardiac myocyte hypertrophy. These stimulations are 
frequently presented in the post-MI heart, activating different kinds of signaling pathways 
within myocytes. Cardiac myocyte hypertrophy is marked by increased volume and number 
of cells, enhanced protein expression, which is consistent with the gene expression profile in 
the developing fetal heart[30]. 
Eventually, because of the fact that increased expression and synthesis of contractile 
proteins cannot be maintained, the compensatory hypertrophy in non-infarcted areas reduces. 
The remaining viable myocardium sustains reduced contractility. This leads to a decline in 
cardiac function and subsequent LV volume overload. As LV end-diastolic volume and 
pressure raises, LV wall thins because myocytes are forced to stretch and expand the 
infarcted regions. Meanwhile, these can further increase LV chamber dilation and wall stress. 
Other factors, such as apoptosis, myocytes rupture, decline in the intercellular space, also 
contributing to wall-thinning and infarct area expansion[24]. In previous post-MI studies 
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performed on mice, an increase in LV end-diastolic volume and wall-thinning outside of 
infarcted areas had been demonstrated as early as 18 days after coronary artery ligation[28, 31]. 
During this time point, the heart is in an irreversible progression towards heart failure. 
Meanwhile, continued biomechanical and chemical stress, serving as a chronic inducer of 
cardiac fibroblasts in the myocardium, worsens the prognosis. Therefore, this constant 
stimulation leads to over-production and deposition of ECM by cardiac fibroblasts. 
Consequently, cardiac fibrosis is initiated and infiltrated into the un-infarcted areas, making 
the myocardium stiffer, and further damage cardiac function[32]. 
1.5 ROS and Nox2 in MI 
While studies show that low levels of reactive oxygen species (ROS) are 
physiologically important, production of excessive amounts of ROS is a key event involved 
in post-MI pathogenesis4. ROS modulate several processes during cardiac remodeling, 
including interstitial fibrosis, and cardiomyocyte apoptosis and hypertrophy[33-34]. 
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Many studies demonstrate that a major source for ROS in the heart comes from a family 
of nicotinamide adenine dinucleotide phosphate- (NADPH) oxidase enzymes[35]. NADPH 
oxidase is a multi-subunit enzyme consisting of membrane proteins (gp91phox otherwise 
known as Nox and p22phox) and several intracellular associated proteins (p47phox, 
p67phox, Rac). Five Nox isoforms (Nox1 to Nox5) exist and are thought to the major 
indispensable subunit. Among these, Nox2 is expressed in cardiomyocytes, fibroblasts, and 
endothelial cells, and is thought to be dominant Nox isoform contributing to cardiac 
superoxide levels (O2-) production[33, 36]. Evidence shows that both in animal models of MI 
and patients with end-stage heart failure, Nox2 expression is significantly increased in the 
infarcted myocardium, primarily in macrophages and myocytes[37-38]. Nox2 knockout mice 
show reduced cardiomyocyte apoptosis and adverse remodeling after MI and attenuate 
interstitial fibrosis following aortic constriction[39].  In addition, as there is no specific 
inhibitor of Nox2, studies from our own laboratory have shown that Nox2 siRNA delivered 
in polymeric nanoparticles can attenuate acute cardiac dysfunction following MI as a 




MicroRNAs are a kind of small, non-coding ribonucleic acids (RNAs). They were first 
discovered as elements essential for development of Caenorhabditis elegans (C.elegans)[41-
44]. Lin-4 was the first reported small non-coding RNA, which was essential for larval 
development of C.elegans. This small RNA was then demonstrated to be able to suppress a 
target protein via RNA::RNA sequence complementary binding within the messenger RNA 
(mRNA) 3’untranslated region (3’UTR) of the target[41, 43, 44]. Let-7, another key small RNA 
involved in regulation of C.elegans development, was then discovered. Since let-7 is highly 
conserved among species, this discovery paved the way for this regulatory mechanism to be 
expanded to multiple specie[43, 45]. In 2001, for the first time, researchers cloned the first set 
of these small RNAs (33 in total) from a human cell line, and coined them as the term 
microRNA[46-48]. After these studies, there are more than one thousand of miRNAs have been 













Figure 1-3: Schematic of microRNA processing. MicroRNAs are transcribed in the 
nucleus by polII which produces a pri-miRNA transcript. This transcript is then 
processed by Drosha into a pre-miRNA sequence, and exported out of the nucleus by 
Exportin5. Dicer then further processes the pre-miRNA into the double stranded 
mature miRNA sequence. Mature miRNA product is incorporated into the RISC 
complex, and after degradation of the anti-sense strand, the miRNA binds to the 3’UTR 
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of target mRNA based off complementary sequence. Target expression is repressed 
either by mechanisms of translation inhibition or mRNA degradation. 
MicroRNAs can locate inter- or intragenic. They are usually transcribed as distinct pri-
miRNA transcripts via polymerase II (Figure 1-3)[49-50]. MicroRNAs can be transcribed both 
as single miRNA hairpins and as polycistronic clusters. After transcription, the pri-miRNA is 
processed through an RNase III enzyme Drosha into a 60-90 nucleotide (nt) pre-miRNA 
construct. Then Exportin5 export this pre-miRNA out of the nucleus. The pre-miRNA is then 
further processed into the double stranded mature miRNA sequence within the cytoplasm. 
Then the RNA-induced silencing complex (RISC) incorporates this 20-25nt long double-
stranded RNA and the mature sequence is released by preferential degradation of the 
antisense strand. The RISC complex is the functional unit of the miRNA machinery. This 
complex will bind to the 3’UTR of the target mRNA based on sequence complementarity[49-
50]. Unlike small interfering RNA (siRNA) the binding of miRNA to mRNA has a degree of 
imperfect complementary. This leads to a different method of functional suppression, 
including both mRNA degradation and translational inhibition[49]. The precise mechanisms 
of repression are still not quite clear but mRNA degradation seems to happen through 
16 
deadenylation and recruitment to processing bodies, while translational inhibition usually 
can occur at the level of initiation or elongation[51]. 
Several clues pointed to a participation of miRNAs in cardiac disease. In failing hearts, 
a profibrotic role was attributed for miR-21[52]. Therapeutic miR-21 antagonism was shown 
to reduce progression of maladaptive fibrosis. Contrary to standard pharmacological agents 
targeting only single molecular pathways, miRs are capable of regulating multiple 
downstream mediators in parallel, thus affecting various signaling cascades. Van Rooij et 
al[53] nicely demonstrated the direct impact of miR-29 expression for fibrotic scar formation 
in the failing heart. Next to the development of cardiac fibrosis, miR-133 was closely linked 
to cardiomyocyte function by altering hypertrophic response[54]. MiRs were also shown as 
therapeutic entry points in several MI-related disease settings (eg, miR-92a, miR-24)[55-56], 
and its use as biomarkers for heart disease has recently been discovered intensively[57-59]. 
1.7 High-throughput miRNA-targets screening system 
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The critical challenge in miRNA therapy for cardiac disease includes identifying 
miRNAs that can target important genes and delivering them into specific cells efficiently. A 
certain miRNA normally has hundreds of targets, which is difficult to validate only by 
database prediction. Most published works using high-throughput miRNA target validation 
are used to identify targets of a miRNA[60-62]. But for a specific pathological disease, in 
which we already know which genes play important roles, it is more useful to find and select 
miRNAs that can target those genes directly. As Nox2 has no specific inhibitor and plays 
such an important role in post-MI pathogenesis, finding new ways to reduce expression 
could generate new therapeutic options. Moreover, to date, there have been no reports of 
miRNAs that target Nox2 directly and reduce expression. In this study, we demonstrate use 
of a self-assembled cell microarray (SAMcell) to find miRNAs that target Nox2 and deliver 
them into myocardial macrophages via acid-degradable polymers previously shown to 
deliver siRNA in to macrophages[40]. The SAMcell system had been demonstrated for its 
efficient and accurate miRNA targeting identification by our previous work[63]. SAMcell 
18 
assays using the 3’UTR of Nox2 identified many potential miRNAs that were then tested in 
reporter cells, as well as mouse and human macrophages. 
 
Figure 1-4: Schematic diagram of the screening strategy to identify miRNAs targeting 
human Nox2. miRNA mimics were printed on the self-assembled cell microarray 
together with the transfection reagent. Hela cells stably expressing enhanced green 
fluorescent protein (eGFP) fused with the 3’UTR from human Nox2 were seeded on the 
array. Human Nox2 siRNA was used as positive control (PC) and scrambled miRNA 
was used as negative control (NC). In total, 266 miRNAs with conserved sequences 
between humans and mice were screened. After bioinformatics analysis and validation, 
three miRNAs were chosen for further study. 
1.8 Polyketal PK3 Nanoparticles. 
 
 19 
Polyketals (PKs) are a class of delivery vehicles formulated from a class of polymers 
that contain pH sensitive, hydrolyzable ketal linkages in their backbone. Unlike the 
predominantly polyester based delivery vehicles currently of use, PKs do not generate acidic 
degradation products as they degrade into acetone and diols[64]. The polymerization strategy 
is such that it is possible to form polymers between any diol and 2,2-dimethoxypropane 
affording great flexibility for generating biomaterials with properties such as variable 
hydrolysis and pH sensitivities suitable for a variety of applications[65, 68]. The properties of 
PKs can be easily modified to alter particle size, shape and porosity. Among these, the 
polyketal copolymer PK3 formed by reacting the diols cyclohexanedimethanol and 1,5-
pentanediol with 2,2-diethoxypropane makes an excellent delivery vehicle for siRNA due to 
its faster hydrolysis at the acidic pH of the endosome. In a previous study where PK3 was 
used to deliver TNF-α siRNA to liver macrophages in vivo, a hydrolysis half-life of 1.8 days 
at pH 4.5 and 39 days at pH 7.4 was reported[69]. Additionally, PK3 is a hard material that is 
water insoluble and can maintain its integrity in vivo due to the high energy cost of being 
exposed to water, providing serum stability[68-69]. Published studies from our laboratory 
20 
demonstrate that polyketal nanoparticles are retained in the myocardium following injection 
and are stable at neutral pH levels[66, 68]. When engaged by macrophages, present in high 
quantities during MI, particles are taken up and trafficked into phagosomes/endosomes 
where they degrade due to the acidic environment. Although the mechanism of release of 
siRNA is not clearly known, it is speculated that after phagocytosis/endosomes, these 
particles hydrolyze and potentially cause an osmotic imbalance within these compartments, 






Figure 1-5: Schematic of PK-siNox2 particle formulation and delivery. (A) Ion-paired 
siRNA:DOTAP and endosomal disruptive agent chloroquine are encapsulated into the 
PK3s via a single emulsion/solvent evaporation procedure generating submicron 
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particles (500 ± 175 nm). (B) The PK3s encapsulating siRNA are intramuscularly 
injected into mice hearts following permanent coronary occlusion (MI) surgery. The 
particles are taken up my macrophages in vivo with high efficiency due to their ability 
to protect siRNA from serum proteins and stimulate phagocytosis and/or endocytosis. 
Once taken up, they degrade in the acidic environment within these compartments due 
to the acid- sensitive ketal linkages in PK3 (also aided by chloroquine) and escape the 












CHAPTER 2.  SAMCELL SCREENING TO TARGET HUMAN NOX2 
2.1 Fabrication of SAMCell 
Glass slides (2.2 cm×2.2 cm) were washed with detergent and miliQ water. After 
dryness, the slides were covered with poly (N-isopropylacryla-mide) (Aldrich) dissolved in 
ethanol (6% (w/v). The slides were etched via a shadow mask by oxygen plasma for 3.5 min 
at 200 W. The reverse transfection protocol refers to previous description32. In brief, 3 µl of 
OptiMEM (Invitrogen), containing sucrose and Lipofectamine 2000 (Invitrogen) were 
transferred to each tube and mixed thor- oughly. Then, 1 µl siRNA (100 µM) was added to 
each tube and the mixture was incu- bated for 20 min at room temperature. Finally, 7.25 µl 
of a 0.2% (w/v) gelatin (Sigma, Type B) solution was added to each tube and mixed 
thoroughly. After ultraviolet sterilization, the reverse transfection reagent was printed either 
on the chip via a nanolitre microfluidic dispenser we recently created33, or on a 
commercially available nanodispenser (Phoenix, Art Robbins Instruments). Next, the slides 
were fixed in a six-well plate by melted wax. About 3 ml 37 °C medium containing 5×105 
cells were transferred in each well. About 24–48 h later, the dishes were moved at room tem- 
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perature for 5 min and washed with PBS for three times to ensure the total removal of the 
polymer. Then the cell microarray was recorded by a microscope system. 
2.2 Construction of Report System 
The 3’UTR of human Nox2 gene was cloned by PCR and linked to the end to eGFP 
protein. To establish stable cell lines, the lentiviral vector containing eGFP and human Nox2 
3’UTR was packaged in 293T cells. After 72 h, eGFP-positive cells were collected by FACS. 
Alternatively, 48 hours after infection, medium was changed, and puromycin (Sigma) was 
added to the medium and the selection was carried out for 3-5 weeks. 
2.3 miRNA-targets screening 
Over 260 miRNAs were printed on SAMcell microarrays. Then, 5 × 105 cells 
containing 3’UTR reporter were transferred in each well. About 24-48 h later, the dishes 
were moved at room temperature for 5 min and washed with PBS for three times to ensure 
the total removal of the polymer. Average fluorescent intensity of each cell island were 
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collected and analyzed. The cut-off value was obtained on the basis of the Kolmogorov-
Smirnov Z-test in 50 control experiments. For each miRNA, at least 6 times were repeated. 
2.4 Screening results 
The top effective miRNAs are listed in Table 1. Three miRNAs, miR-106, miR-148b, 
and miR-204 were selected for further study after literature research and miRNA target 
prediction. Each of them have one or more predicted binding sites in human Nox2 3’UTR 
according to Targetscan database, shown in Table 2. 
 
Table 1: Top listed results of SAMCell 
miRNA Fold Change P-value 
miR-106b 0.9000 0.0003 
miR-148b 0.9010 0.0001 
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Table 1 continued 
miR-21 0.9049 0.0191 
miR-135b 0.9150 0.0004 
miR-296-5p 0.9155 0.0005 
miR-590-5p 0.9209 0.1019 
miR-33a 0.9233 0.0289 
let-7f-1-3p 0.9250 0.0498 
miR-29c* 0.9258 0.0037 
let-7i 0.9265 0.0268 
miR-204 0.9278 0.0082 
miR-221 0.9315 0.1212 
miR-190 0.9337 0.1169 
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Table 1 continued 
miR-7 0.9355 0.0581 
miR-331-3p 0.9362 0.0463 
 
Table 2: miRNAs-Nox2 predicting binding sites from Targetscan database 






                                                        | | | | | | | 





                                                          | | | | | | 
3'   UGUUUCAAGACAUCACGUGACU 
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5'  ...UCAAUUUUAGAAUCAAAAGGGAA... 
                                                            | | | | | | | 




5'    ...AAAAUAAAAAAGGCAAAAGGGAG... 
                                                          | | | | | | | 








CHAPTER 3.  SELECTED MIRNAS FUNCTIONAL VALIDATION 
3.1 Cell Culture 
293T and Hela cells were cultured in high-glucose Dulbecco’s Modified Eagle Medium 
(DMEM) containing 10% fetal bovine serum (FBS), 100 units/ml penicillin and 0.1 mg/ml 
streptomycin (P/S). RAW 264.7 and THP-1 cells were cultured RPMI 1640 containing same 
amounts of FBS and P/S as above. All cells were cultured under humidified conditions in 5% 
CO2 at 37°C. When seeding, cells were washed with PBS and incubated in 0.25% trypsin 
containing 5mmol/L EDTA. After centrifugation, cells were diluted in media, counted via 
hemocytometer, and then seeded at the appropriate concentration. 
3.2 miRNA Transfection 
miRNA mimics were obtained from GenePharma and Sigma. To achieve transient 
expression, plasmids and miRNA mimics were transfected using Oligofectamine 
(Invitrogen) following the protocol below: 
 
 29 
1. One day before transfection, plate cells in 100 µL of growth medium without     
antibiotics so that cells will be 30–50% confluent at the time of transfection. 
2. For each transfection sample, prepare complexes as follows: 
a. Dilute 1 µL of a 20 µM stock oligonucleotide in 16 µL of Opti-MEM I 
Reduced Serum Medium without serum to a final volume of 17 µL. Mix gently. 
b. Mix Oligofectamine Reagent gently before use, then dilute 0.4–0.8 µL in 
Opti-MEM I Mediumwithout serum to a final volume of 3 µL. Mix gently and incubate for 
5–10 minutes at room temperature. 
c. Combine the diluted oligonucleotide with diluted Oligofectamine Reagent 
(total volume = 20 µL). Mix gently and incubate for 15–20 minutes at room temperature (the 
solution may appear cloudy). 
3. While complexes are forming, remove the growth medium from the cells and 
wash once with medium without serum. Add 80 µL of medium without serum to each well 
containing cells. 
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4. Mix the 20 µL of complexes (from step 2c of this procedure) gently, and add 
to the cells. 
5. Incubate the cells at 37°C in a CO2 incubator for 4 hours. 
6. Add 50 µL of growth medium containing 3X the normal concentration of 
serum without removing the transfection mixture. 
3.3 Luciferase Assay 
The 3’UTR of human or mouse Nox2 were cloned into pGL3 plasmids 3’UTR to the 
firefly luciferase gene. Four x 104 293T cells were co-transfected with 200 ng of the 
indicated pGL3 firefly luciferase construct and 20 ng of a pGL3 Renilla luciferase used as a 
normalization control. At the same time, the indicated miRNA expression plasmid or mimics 
were transfected. After 48 hours, cells were lysed and luciferase activities were measured 
using the Dual Luciferase Reporter Assay System (Promega). 
3.4 RNA Isolation 
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Total RNA from cells was isolated using Trizol (Invitrogen) according to the 
manufacturer’s protocol. Briefly speaking, rinse cell monolayer with ice cold PBS once. Lyse 
cells directly in a culture dish by adding 1 ml of TRIZOL Reagent per 3.5 cm diameter dish 
and scraping with cell scraper. Pass the cell lysate several times through a pipette. Vortex 
thoroughly. The amount of TRIZOL reagent added is based on the area of the culture dish (1 
ml per 10 cm2) and not on the number of cells present. An insufficient amount of TRIZOL 
Reagent may result in DNA contamination of the isolated RNA. Add 0.2 ml of chloroform per 
1 ml of TRIZOL Reagent. Cap sample tubes securely. Vortex samples vigorously for 15 
seconds and incubate them at room temperature for 2 to 3 minutes. Centrifuge the samples at 
no more than 12,000 x g for 15 minutes at 2 to 80C. Following centrifugation, the mixture 
separates into lower red, phenol- chloroform phase, an interphase, and a colorless upper 
aqueous phase. RNA remains exclusively in the aqueous phase. Transfer upper aqueous phase 
carefully without disturbing the interphase into fresh tube. Measure the volume of the aqueous 
phase. Precipitate the RNA from the aqueous phase by mixing with isopropyl alcohol. Use 0.5 
ml of isopropyl alcohol per 1 ml of TRIZOL Reagent used for the initial homogenization. 
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Incubate samples at 15 to 30oC for 10 minutes and centrifuge at not more than 12,000 x g for 
10 minutes at 2 to 4oC. The RNA precipitate, often invisible before centrifugation, forms a gel-
like pellet on the side and bottom of the tube. Remove the supernatant completely. Wash the 
RNA pellet once with 75% ethanol, adding at least 1 ml of 75% ethanol per 1 ml of TRIZOL 
Reagent used for the initial homogenization. Mix the samples by vortexing and centrifuge at 
no more than 7,500 x g for 5 minutes at 2 to 8
o
C. Repeat above washing procedure once. 
Remove all leftover ethanol. Air-dry or vacuum dry RNA pellet for 5-10 minutes. Do not dry 
the RNA pellet by centrifuge under vacuum. It is important not to let the RNA pellet dry 
completely as this will greatly decrease its solubility. Partially dissolved RNA samples have 
an A260/A280 ratio < 1.6. Dissolve RNA in DEPC-treated water by passing solution a few 
times through a pipette tip. 
3.5 Complementary DNA (cDNA) Synthesized 




1. Mix and briefly centrifuge each component before use. Preheat the thermal 
cycler to 65°C. 
2. Combine the following in a 0.2–mL, thin-walled PCR tube on ice: 
up to 5 µg total RNA: n µL 
Primer (50 µM oligo(dT)20, or 50 ng/µL random hexamers): 1 µL 
Annealing Buffer: 1 µL 
RNase/DNase-free water to 8 µL 
3. Incubate in a thermal cycler at 65°C for 5 minutes, then immediately place on 
ice for at least 1 minute. Collect the contents of the tube by brief centrifugation. 
4. Add the following to the tube on ice: 
2X First-Strand Reaction Mix: 10 µL 
SuperScript III/RNaseOUT Enzyme Mix: 2 µL 
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5. Vortex the sample briefly to mix, and collect by brief centrifugation. Incubate 
as follows: 
a Oligo(dT)20 or GSP primed: 50 minutes at 50°C 
b Random hexamer primed: 5–10 minutes at 25°C, followed by 50 minutes at 
50°C 
6. Terminate the reactions at 85°C for 5 minutes. Chill on ice. 
7. Store the cDNA synthesis reaction at –20°C, or proceed directly to PCR. 
3.6 Real time PCR 
Real time PCR was performed using Power SYBR Green (Invitrogen) master mix with 
Applied Biosystems StepOne Plus real time PCR system. The primers used are listed in 





Table 3: Real-time PCR primers sequence 




























3.7 Intracellular Protein Isolation. 
Intracellular protein was isolated according to the following protocol: 
1. Place the cell culture dish on ice and wash the cells with ice-cold PBS. 
2.  Aspirate the PBS, then add ice-cold lysis buffer (1 mL per 107 cells/100 mm dish 
150 cm2 flask; 0.5 mL per 5x106 cells/60 mm dish/75 cm2 flask). 
3.  Scrape adherent cells off the dish using a cold plastic cell scraper, then gently 
transfer the cell suspension into a pre-cooled microcentrifuge tube. Alternatively cells can be 
trypsinized and washed with PBS prior to resuspension in lysis buffer in a microcentrifuge 
tube. 
4.  Maintain constant agitation for 30 min at 4°C. 
5.  Centrifuge in a microcentrifuge at 4°C for 20 min at 12,000 rpm. 
6.  Gently remove the tubes from the centrifuge and place on ice, aspirate the 
supernatant and place in a fresh tube kept on ice, and discard the pellet. 
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3.8 Western Blot 
Western blot analysis was performed using previously described protocols established 
in our group. Briefly, samples containing 40 µg total proteins were separated by 
electrophoresis on a 1.0% (wt/vol) agarose (molecular biology grade; GIBCO BRL) gels. 
The electrophoresis buffer [1X Tris-acetate-EDTA (TAE)], contains 0.1% (wt/vol) SDS, 
1mM EDTA, and 40mM Tris acetate (pH 8.0). Samples were solubilized in sample buffer 
consisting of 2.5% (wt/vol) SDS, 4.5 M urea, 5% (vol/vol) β-mercaptoethanol, 25% (vol/vol) 
glycerol, 0.005% (wt/vol) bromophenol blue, and 0.08 M Tris HCl at pH 7.5. Samples were 
then denatured at 95°C for 10 minutes and loaded into sample wells in a horizontal gel 
apparatus (GIBCO BRL). The electrophoresis ran at room temperature at 35 V for several 
hours, and then at 15 V overnight. Proteins were transferred under positive pressure at 75 
mmHg for 2.5 hours from the gel onto a polyvinylidine difluoride (PVDF) membrane 
(Millipore, Bedford, MA) in a 4X saline- sodium citrate (SSC) buffer made from a 20X 
stock (Invitrogen). The membrane was allowed to dry overnight (or for at least 2 hours) and 
then submersed in methanol and rinsed 2X with ddH2O. The membrane incubated for 1 hour 
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at room temperature in a milk blocking solution made of 5% non-fat dry milk in 40 mL of 
1X PBS containing 0.05% Tween-20 which was added immediately prior to use (PBST). 
Immunostaining was carried out with the appropriate antibody (see below) in a 2.5% milk 
blocking solution for 1 hour at room temperature, and then at 4°C overnight. This was 
followed by secondary immunodetection using an appropriate secondary antibody labeled 
with horseradish peroxidase for 1 hour at room temperature. Chemiluminescence was carried 
out using 6 mL (1:1 v/v) of SuperSignal West Dura Chemiluminescent Substrate 
(Thermoscientific) with a 2 minutes incubation time (manual shaking). The membrane was 
visualized on Blue Ultra Autrad film (GeneMate). All scans of films are taken using a GS-
800 Calibrated Densitometer and ImageJ software. 
3.9 Results 
To validate each miRNA’s ability to suppress human Nox2, we performed luciferase 
assays in 293T cells cloned with the 3’UTR of Nox2 downstream of luciferase. As shown in 
Figure 3-1A, all of the three miRNAs significantly decreased luciferase expression 
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compared to control (miR-106b=78.5+8.6%, P<0.01; miR-148b=78.6+11.1%, P<0.01; miR-
204=56.2+8.4%, P<0.001). To determine whether their regulation was conserved, we also 
validated the selected miRNAs using mouse Nox2 3’UTR downstream of luciferase. Similar 
to human Nox2, luciferase containing mouse Nox2 3’UTR was also significantly decreased 
by these miRNAs compared to control group (miR-106b=66,6+6.8%, P<0.001; miR-
148b=70.1+8.2%, P<0.001; miR-204=46.7+2.7%, P<0.001, Figure 3-1B). 
 
Figure 3-1: miRNAs targeted both humans and mice Nox2. A and B, Relative luciferase 
activity in Hela cells transfected with indicated miRNAs or control vector with human 
(A) and mouse (B) Nox2 3’UTR driven reporter constructs, n=5. 
We also transfected these miRNAs mimics to induced human macrophages (THP-1 
cells) and a mouse macrophage cell line (RAW 264.7). Nox2 mRNA and protein levels were 
detected by real-time PCR and western blot, respectively. As expected, compared to a 
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scrambled control miRNA group, all 3 miRNAs decreased both human and mouse Nox2 
expression at the gene and protein level by about 40% (Figure 3-2C and D). 
 
 
Figure 3-2: miRNAs regulated both humans and mice Nox2 expression. C and D, Real-
time PCR for Nox2 in PMA induced THP-1 (C) and RAW 264.7 (D) cells 48 hours after 
transfection with indicated miRNA or control vector. GAPDH was used as the loading 
control, n=3. E and F, Immunoblots for Nox2 in PMA induced THP-1 (E) and RAW 
264.7 (F) cells 48 hours after transfected with indicated miRNAs or control vector. 





CHAPTER 4.  IN VITRO FUNCTIONAL KNOCKDOWN OF NOX2 
DOWNSTREAM PRODUCTION 
4.1 Superoxide Production Staining with Probe 
To determine whether Nox2 knockdown by miRNAs resulted in functional changes, we 
transfected THP-1 induced and RAW 264.7 macrophages with miRNAs separately and 48 
hours later, they were stimulated with PMA to induce O2- production. ROSstar 650 dye, a 
fluorescent probe for intracellular ROS, was then added to the cells. Fluorescence intensity 
was expressed as fold change in O2- production normalized to basal O2- levels. 
4.2 Results 
As shown in Figure 4A, after stimulation with PMA, O2- production was increased, 
while each miRNA treatment group showed significantly decreased levels in O2- production 
compared to the control group in THP-1 induced (upper) and RAW 264.7 (bottom) 
macrophages. Quantification results were shown as Figure 4B for THP-1 induced 





Figure 4: miRNAs inhibited superoxide production in humans and mice macrophages. 
Superoxide production levels in THP-1 (A) and RAW 264.7 (C) cells were detected with 
ROSstar dye staining after stimulated by PMA and transfected with indicated miRNAs 
or control vector, n=3. Scar bar = 100 µm. B and D, Quantification of superoxide 
production levels in THP-1 (B) and RAW 264.7 (D) cells by comparing fluorescence 




CHPATER 5.  NANOPARTICLE UPTAKE BY MACROPHAGES 
5.1 Polyketal (PK3) Synthesis 
PK3 was synthesized as described in our prior publications[69]. Briefly, the diols, 
cyclohexanedimethanol and 1,5-pentanediol were dissolved in distilled benzene and heated 
to 100°C. Recrystallized p-toluenesulfonic acid (PTSA) was dissolved (~1 mg) in ethyl 
acetate and added to the benzene solution to catalyze the reaction. The polymerization 
reaction was initiated by the addition of equimolar 2,2-diethoxypropane (DEP). Additional 
2,2-dimethoxy propane (DMP) and benzene were subsequently added to the reaction to 
compensate for loss of volume in the form of ethanol/methanol and the solvent benzene that 
had distilled off. After 48 h, the reaction was stopped with triethylamine and isolated by 
precipitation in cold hexanes. The solid polymer was filtered off, rinsed in hexanes and 
vacuum dried prior to storage at -20°C. Polymer molecular weight/polydispersity was 
confirmed by gel permeation chromatography. 
5.2 Preparation of miRNA-loaded PK3 particles 
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PK3-miRNA particles were prepared following the protocol for PK3-siRNA 
particles[40]. Briefly, 1 mg miRNA in water and 2.2 mg of cationic lipid N-[1-(2,3-
Dioleoyloxy)propyl]-N,N,Ntrimethylammonium methysulfate (DOTAP) dissolved in 
dichloromethane (DCM) were brought to one phase by addition of 1.05 
mL of methanol. After 15 min incubation, an additional 0.5 mL of water and DCM were 
added and the mixture was vortexed, and centrifuged at 750 rpm for 5 min. The 
miRNA:DOTAP complex in the bottom organic layer was encapsulated in PK3 via an 
oil/water single emulsion procedure, using DCM as the oil phase and polyvinyl alcohol 
(PVA) as the surfactant stabilizer. 1 mL of DCM containing ion-paired miRNA was added to 
40 mg of PK3 with 1 mg of chloroquine free base. This solution was homogenized into 8 mL 
of 5% (w/v) PVA solution at the highest setting in the Power Gen 500 (Fisher Scientific) for 
30 seconds, and sonicated at an intermediate speed (Sonic dismembrator model 100, Fisher 
Scientific) with 10 pulses of 1 sec duration. The emulsion was then dispersed in a 20 mL of 
0.5% PVA solution and stirred for a period of 4-5 h to allow the DCM to evaporate. The 
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resulting particles were isolated by centrifugation (15000 rpm, 20 min), washed three times, 
freeze-dried and stored at -20°C for further use. 
5.3 In vitro delivery of PK3-miRNA particles 
For in vitro studies, RAW 264.7 macrophages or PMA induced THP-1 cells were plated 
in 6-well plates at a density of 1 x 106 cells per well. After 24 h, cells were treated with 
indicated PK3-miRNA particles at a concentration of particles equivalent to 2 µg 
miRNA/well. For gene expression studies, following 48 hours of treatment, the cells were 
harvested and RNA or protein extracted. For assessment of functional activity of Nox2-
NADPH, the cells were kept in wells for analysis of O2- production. 
5.4 Results 
After validation of individual miRNA function on Nox2 expression and downstream O2-
production, we sought to validate our previously used in vivo delivery system with miRNA 
in cultured cells.  miRNAs encapsulated within PK3 polymer (PK-miRNA) showed similar 
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loading levels as our prior publications (1 µg per mg particle).  Cells were incubated with the 
indicated PK-miRNA formulation and expression of the delivered miRNA was evaluated 
with real-time PCR.  As shown in in Figure 5A, each formulation was able to increase 
expression of their respective cargo at least 500-fold, indicating effective delivery. 
We treated RAW 264.7 macrophages with PK-miRNA particles for 48 hours and Nox2 
mRNA expression level was determined by real-time PCR. As shown in Figure 5B, 
treatment with any of the particle formulations significantly reduced Nox2 gene expression 
(miR-106b=58.9+5.7%, P<0.001; miR-148b=63.7+7.9%, P<0.001; miR-204=51.1+12.8%, 
P<0.001). O2- production was also measured and, similarly to gene expression, treatment 
with any PK-miRNA particle significantly decreased production as compared to the control 
group (PK3-NC, Figure 5C and 5D). 
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Figure 5: PK3-miRNAs nanoparticles redued Nox2 expression and activity in RAW 
264.7 cells. A, Fold change of miRNAs levels in RAW 264.7 cells after treated with 
indicated PK3-miRNAs nanoparticles by real-time PCR. U6 was used as the loading 
control, n=3. B, Real-time PCR of Nox2 in RAW 264.7 cells after treatment with 
indicated PK3-miRNA or control nanoparticles. GAPDH was used as the loading 
control, n=3. C and D, Representative images (C) and quantification (D) of superoxide 
production levels in RAW 264.7 cells treated with indicated nanoparticles by ROSstar 




CHPATER 6.  PK3-MIRNAS NANOPARTICLES IN VIVO DELIVERY 
6.1 Myocardial Infarction and Particle Injection 
Studies were conducted under a randomized and blinded manner. Adult male C57BL/6 
mice (>8 weeks) were used and assigned to five groups. One group was subjected to sham 
surgery, while the other four groups received permanent myocardial infarction. The surgeries 
were conducted as described previously[68]. Briefly, the animals were anesthetized by 
isoflurane. Following tracheal intubation, the heart was exposed by separation of the ribs. 
Myocardial infarction was achieved by ligation of the left anterior descending coronary artery. 
For mice getting particle injections, 50 µL of indicated particle was injected into the cyanotic 
ischemic zone through a 30-gauge needle immediately after ligation. The dose of miRNA 
injected was 5 µg/kg. After injection, the chests were closed and animals were recovered on a 
heating pad. Functional assessments were made at 3 days following surgeries using 
echocardiography. These studies conformed to the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health and all animals studies were 
approved by Emory University Institutional Animal Care and Use Committee. 
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6.2 Immunohistochemistry 
Fresh heart tissue was frozen in Tissue-Tek OCT and 5 µm sections were made. After 
washing with PBS, sections were fixed by 4% formaldehyde solution an then incubated with 
goat serum for 1 h. Nox2 antibody diluted in goat serum was added to the sections and 
incubated at 4°C overnight. After that, sections were washed 3 times using PBS-Tween and 
incubated with fluorescent secondary antibody for 2 h at room temperature. Nuclei were 
stained by Hoechst dye. Images were taken by Nikon at identical exposures and analyzed by 
ImageJ software. 
6.3 Echocardiography 
Anesthetized mice were subjected to echocardiography 3 days after MI surgery. Short axis 
values of left ventricular diameter were obtained using a Vevo 770 small animal ultrasound 
system (Visualsonics). An average of 3 consecutive cardiac cycles was used for each 
measurement and performed three times in an investigator-blinded manner. Fractional 
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shortening (FS) was calculated as (end-diastolic diameter – end-systolic diameter)/end-diastolic 
diameter and expressed as a percentage. 
6.4 Results. 
To determine the in vivo efficiency of miRNA mediated-Nox2 suppression, adult male 
C57BL/6 mice were randomized into 5 treatment groups. Control mice were subjected to sham 
surgery, while the other four groups received MI surgery followed by injection of PK-miRNA 
or a negative control scrambled miRNA particle (PK-NC). At 3-days post injury, hearts were 
harvested and expression of Nox2 was determined by immunofluorescence staining of frozen 
sections. As shown in Figure 6-1A and B, there was a significant increase in Nox2 staining 
with PK-NC treatment following MI as compared to sham mice (about 3-fold, P<0.001). 
Compared to PK-NC group, each PK-miRNA treatment group demonstrated significantly 
reduced staining of Nox2 (miR-106b=43.2+6.8%, P<0.001; miR-148b=24.8+6.3%, P<0.001; 
miR-204=35.9+5.1%, P<0.001). Additionally, O2- levels were determined by DHE staining on 
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frozen sections. Similar to Nox2 expression levels, each PK-miRNA treatment significantly 








Figure 6-1: PK3-miRNAs nanoparticles inhibited Nox2 expression and activity in vivo. A 
and B, Representative images (A) and quantification (B) of Nox2 (red) levels by in situ 
immunostaining on frozen sections from indicated treatment mice heart tissues. Cell 
nuclei were stained by Hoechst (blue), n=5. C and D, Representative images (C) and 
quantification (D) of superoxide production levels by DHE staining on frozen sections 
from indicated mouse heart tissues. Cell nuclei were stained by Hoechst, n=5. Scar bar = 
100 µm. **p<0.01; ***p<0.001 (t-test). 
To determine the effect of PK-miRNAs delivery on acute cardiac function after MI, 
echocardiography data was collected 3 days after injury. As shown in Figure 6-2A, B and C, 
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MI significantly reduced cardiac function as measured in absolute change in fractional 
shortening and ejection fraction 3 days post-injury. Treatment with each PK-miRNA particle 
significantly improved function, restoring it to sham levels. 
 
Figure 6-2: PK3-miRNA nanoparticles improved cardiac function after MI. A, 
Echocardiographic pictures of mice 3 days after indicated treatment. B and C, 
Echocardiographic parameters Fractional shortening (B) and Ejection fraction (C) from 




CHPATER 7.  DISCUSSION 
Substantial evidence shows that oxidative stress due to excessive ROS such as O2- plays 
an important role in the development of post-MI cardiac dysfunction[70-71]. Antioxidant 
treatment following MI in animal models improves cardiomyocyte survival, attenuates 
ventricular remodeling, and results in preservation of left ventricular function[72]. NAPDH 
oxidases are major sources of O2- in the heart and the family of gp91 proteins (Nox 1-5) is an 
important catalytic unit of the NADPH oxidase[71]. Nox2 is mainly expressed in 
macrophages, fibroblasts, endothelial cells and cardiomyocytes[73] and is significantly 
increased in the myocardium following MI with the massive influx of inflammatory cells[74-
75]. Nox2 is also increased in human cardiomyocytes following MI[75].  Nox2 knockout mice 
are protected from post-MI dysfunction[39], and studies from our own laboratory show that 
siRNA against Nox2 encapsulated in nanoparticles can protect against acute MI 
dysfunction[40]. Therefore finding additional was to target Nox2 could be a promising 
therapeutic approach for preserving function following acute MI. 
56 
In the current report, we successfully identified several miRNAs targeting Nox2 with 
the use of a high-throughout miRNA-target screening system and validated their targeting 
using a luciferase reporter system with the 3’UTR of Nox2. We also confirmed their function 
by testing Nox2 expression and function in both human and 
mouse macrophage cell lines. To date, there had been no studies that identified a miRNA that 
directly bound the Nox2 3’UTR and decreased expression. The SAMcell assay provided a 
straightforward way to identify miRNAs that target a specific gene. In our previous studies, 
the performance of this system had been demonstrated using a phenotypic approach to 
determine miRNAs that regulated processes involved in cancer[63]. In this study, miRNAs 
were selected that were conserved between human and mouse in order to test potential 
human targets in mouse models of MI. Three specific miRNAs were chosen for more 
detailed analysis due to prior publications underscoring their involvement in post-MI 
healing. Following MI, miR-106b reduced apoptosis via inhibition of p21 expression[76], and 
has also been shown to target the pro-inflammatory cytokine IL-8[77]. The second hit, miR-
148b, has been reported to negatively regulate LPS-induced cytokine production in dendritic 
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cells, including IL-6, IL-12, and TNF-a, and plays an important role in immune 
regulation[78]. In addition, a significantly decreased expression of miR-148b was observed in 
isoproterenol-induced myocardial injury and fibrosis; expression was increased when 
apocynin treatment was used to reverse this[79]. Finally, our third hit, miR-204, was 
decreased after ischemia-reperfusion (IR) injury in mice and overexpression of miR-204 
protected the cardiomyocytes against IR-induced autophagy[80]. 
After selection of these three miRNAs, their inhibition of both human and mouse Nox2 
was validated by several methods. Luciferase assays using the Nox2 3’UTR demonstrated 
they could each decrease Nox2 expression directly by canonical miRNA regulation. Real-
time PCR and western blot studies confirmed that all three miRNAs decreased Nox2 levels 
at the gene and protein levels (Figure 3-2). DHE staining for PMA-induced superoxide 
levels (a surrogate of Nox2 activity) also showed the functional benefit of the miRNA-
induced decrease in Nox2 levels. There was no significant additive effect by delivery of all 
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three miRNAs together compared to the single miRNA alone both for Nox2 expression level 
and O2- production level as shown in Figure 7-1 and 7-2. 
 
Figure 7-1: Comparison of inhibition effects on Nox2 by miRNAs. Real-time PCR for 
Nox2 mRNA in RAW 264.7 after transfection with indicated miRNA or a mixture of all 
3 miRNAs normalized to miR-106b treatment.  Data show no difference between 


























Figure 7-2: Combination of three miRNAs did not have additive effect on Nox2 activity. 
Quantification of relative fluorescence intensity with DHE staining in RAW 264.7 after 
transfection with indicated miRNA, result of miR-106b used as control. No significant 
difference among four groups, n=3. (p>0.05, t-test). 
Once miRNAs were selected and validated, we sought to utilize an efficient delivery 
system for targeting macrophages in vivo. Polyketals are a class of delivery vehicles 
formulated from a class of polymers that contain pH-sensitive, hydrolyzable ketal linkages in 
their backbone. We had used the polyketal PK3 to deliver miRNA to bone marrow 
mononuclear cells to induce pluripotency[32]. There was no difference in miRNA transfection 




















(Figure 7-3). Additional published studies from our laboratory demonstrated that PK3 
nanoparticles were retained in the myocardium after injection and could be used to deliver 
siRNA following MI in mice[40]. When engaged by macrophages, particles were taken up 
into phagosome/endosomes where they degrade due to the acidic environment, leading to 
release of cargo into the cytoplasm of macrophages (over 80% transfection efficiency). In 
that study we successfully delivered Nox2 siRNA into cardiac macrophages by PK3 particles 
and observed a significant improvement in heart function after MI. 
 
 
Figure 7-3: Comparison of miRNA transfection efficiency between Oligofectamine and 
PK3 nanoparticles. Real-time PCR for miR-106b in RAW 264.7 after transfection equal 
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amount of miR-106b by Oligofectamine (OF-miR-106b) and PK3 nanoparticles (PK3-
miR-106b), n=3. p>0.05 (t-test). 
Despite our prior study showing beneficial effects of delivery of siRNA to Nox2, 
delivery of miRNA might have potential advantages. Firstly, miRNA is more natural as there 
is no siRNA in mammalian cells. miRNA is viewed as endogenous and purposefully 
expressed products in an organism’s own genome, whereas siRNA is thought to be primarily 
exogenous in origin, derived directly from viruses, transposons, or transgene triggers[81]. 
Additionally, introduction of too much siRNA could result in nonspecific events due to 
activation of innate immune response[82]. Secondly, miRNA could target many genes and 
sometimes from the same pathways. For example, let-7, which was shown to be able to 
directly regulate some key cell cycle proto-oncogenes, e.g., RAS, CDC25a, CDK6, and 
cyclin D at the same time, was a key regulator of cell proliferation[83]. Likewise, miR-23b 
plays an important role in tumor metastasis since it regulates a cohort of prometastatic 
targets, including FZD7, MAP3K1, TGFBR2 and PAK2[84]. To validate this hypothesis in 
this study, we examined expression levels of other pro-inflammatory genes such as IL-1β, 
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IL-6 and TNF-a by real-time PCR in RAW 264.7 macrophages after transfection with 
miRNAs. As Figure 7-4, 7-5 and 7-6 shown, these miRNAs significantly decreased the 
mRNA expression level of these pro-inflammatory genes as well, except miR-204 on TNF-a. 
 
 
Figure 7-4: Identified miRNAs inhibited IL-1β expression. Real-time PCR for IL-1β 





Figure 7-5: miRNAs inhibited IL-6 expression. Real-time PCR for IL-6 mRNA in RAW 
264.7 after transfection with indicated miRNA. n=3. **p<0.01 (t-test). 
 
Figure 7-6: miRNAs inhibited TNF-α expression. Real-time PCR for TNF-α mRNA in 
RAW 264.7 after transfection with indicated miRNA. n=3. **p<0.01, ***p<0.001 (t-
test). 
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We next examined the efficacy of these particles in vivo, in a mouse model of MI. 
Similar to our prior studies, we delivered particles immediately following ligation to the 
border zone of the infarct. In keeping with published studies[37-39], both Nox2 levels and 
superoxide levels were significantly increased following MI (Figure 4B and 4D). While 
Nox2 levels have been shown to be upregulated in cardiomyocytes, most staining indicated 
non-cardiomyocyte origin, likely infiltrating inflammatory cells.  While we did not identify 
the source of the superoxide, it was also likely inflammatory cells based on prior studies[71-
72]. While it is possible that Nox2 was increased in myocytes, our published studies show 
that polyketals are not efficiently taken up by cardiomyocytes without surface modification 
of the nanoparticles[69, 85]. It would be interesting to encapsulate the miRNAs in these 
modified particles and determine whether miRNA-mediated knockdown of Nox2 in 
cardiomyocytes is sufficient for protection, though this would be unlikely due to the large 
influx of inflammatory cells. Additionally, we did not measure other ROS such as hydrogen 
peroxide (H2O2), which could also mediate damage. The role of H2O2 in acute MI is 
controversial and it remains a debate as to whether this is a valid target as H2O2 is also 
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involved in important physiological processes. It is also likely that reduced levels of O2- also 
resulted in decreases in H2O2 and understanding this balance could be an interesting topic for 
future consideration. After treatment with any PK3-miRNA, Nox2 expression and O2- levels 
were reduced significantly compared to the empty particle group. More importantly, an 
improvement in cardiac function was observed in each PK3-miRNA formulation treatment 
group. These results corroborated reports that knockdown of Nox2 improves cardiac 
function after MI. 
In conclusion, we have found novel miRNA regulation of Nox2 expression by utilizing 
a high throughput miRNA-target screening method, the SAMcell assay, to narrow down 
potential targets, specifically miR-106b, 148b, and 204. We validated the results in 
transfected cells, as well as human and mouse macrophages. Combined with our efficient 
macrophage-specific delivery approach, these miRNAs were able to reduce Nox2 expression 
and activity in vivo, resulting in improved acute function. With the robust nature of these 
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systems, other inflammatory molecules can be studied to determine optimal miRNA 













CHPATER 8.  FUTURE WORK 
Despite the promising results from this study, there are still lots of work need to be 
completed in the future. First of all, only three miRNAs are selected from the screening 
results. We need to demonstrate if other miRNAs can inhibit Nox2 as well, or even with 
better effects. Furthermore, in order to move this PK3 nanoparticles delivery system into 
clinical applications, we need to test this system in more animal models, such as porcine and 
non-human primate model. Finally, as macrophages play a significant role in lots of 
inflammation related diseases, we can expect this delivery system to be functionally utilized 






CHPATER 9.  OTHER PROJECT DURING PH.D. PROGRAM: 
BIOCOMPATIBILITY ASSESSMENT OF DETONATION 
NANODIAMOND IN NON-HUMAN PRIMATES USING URINE, 
HEMATOLOGIC, AND HISTOLOGICAL ANALYSIS 
9.1 Summary 
Detonation nanodiamonds (DNDs) have been widely studied for various applications in 
biomedical area, including magnetic resonance imaging and cancer therapy. They have several 
unique properties, such as faceted surfaces that mediate water coordination and drug binding. 
These give DNDs significantly enhancements in the efficiency and safety in imaging and drug 
delivery. In addition, DNDs have been shown to be well-tolerated by many biocompatibility 
studies. Consequently, there is a high demand for comprehensive assessment of DND safety in 
large animal preclinical models. Here we demonstrated a DND biocompatibility study in non-
human primates. This non-human primate study was performed as a multiple dose, dual 
gender and long-term observation in both standard/clinically relevant and elevated dosing 
cohorts that lasted for six months and included comprehensive urine, serum, histological, and 
body weight analysis. The results from these studies indicate that DNDs are well-tolerated at 
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clinically relevant doses and examination of dose-dependent changes in biomarker levels 
provides important directions for the following in-human validation of DNDs for clinical 
imagin and drug delivery.
9.2 Introduction 
9.2.1 Nanodiamonds 
Nanodiamond particles produced by detonation were first discovered in the 1960s[86], 
while they kept unknown to most of the world until the end of the 1980s[87]. After that, a series 
of significant breakthroughs were achieved that leading to a broader interests in these 
particles. First of all, it became available to get individual diamond particles in colloidal 
suspensions with diameters of 4-5 nm[88]. Meanwhile, fluorescent nanodiamonds were used by 
investigators as a non-toxic alternative for imaging in biomedical field[89]. Finally, researchers 
demonstrated that nanodiamonds were less toxic compared to other carbon nanoparticles[90-91], 
which largely broader their applications areas. 
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Nowadays, there are various kinds of nanodiamonds available for research. The 
technologies used to synthesized nanodiamonds include detonation technique, lase ablation[92], 
plasma-assisted chemical vapour deposition[93], ion irradiation of graphite[94] and ultrasound 
cavitation[95]. 
9.2.2 Synthesis of Nanodiamonds 
Nanodiamonds can be manufactured by explosives in moleculars. This method provides a 
source of carbon and energy for the conversion as well. The detonation happens in a closed 
chamber filled with an inert gat or water coolant, called dry or wet synthesis, respectively. The 
product, detonation soot, is a mixture of diamond particles with 4-5 nm in diameter and other 
carbon allotropes and impurities. These impurities can be inside the nanodiamond aggregates 













Figure 9-1: In order to synthesize nanodiamonds, explosives with a negative oxygen 
balance (for example a mix of 60 wt% TNT (C6H2(NO2)3CH3) and 40 wt% hexogen 
(C3H6N6O6)) are detonated in a closed metallic chamber in an atmosphere of N2, CO2 and 
liquid or solid H2O. After detonation, diamond-containing soot is collected from the 
bottom and the walls of the chamber. 
9.2.3 Properties of Nanodiamonds 
Nanodiamond is a kind of excellent material in many respects, including superior 
hardness and Young’s modulus, biocompatibility, optical properties and fluorescence, 
electrical resistivity, chemical stability, and great thermal conductivity. 
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Fluorescent particles can be produced by linking[96] or adsorbing[97] different fluorophores 
into the nanodiamonds. These conjugated nanodiamonds can go through cellular 
compartments without affecting cell viability and degradation of fluorophore for quite a long 
time. Fluorescent nanodiamonds combine the advantages of semiconductor quantum dots, 
such as small size, high photostability, multicolor fluorescence, with biocompatibility and non-
toxicity. This property gives them the potential application for in vivo imaging applications[98]. 
Quite a lot of studies have been made to demonstrate nanodiamonds affects on cell viability, 
gene expression activity, and in vivo mechanistic and physiological behavior[99-100]. 
Nanodiamonds were reported to be of low pulmonary toxicity and intravenously administered 
nanodiamonds complexes did not change serum indicators of liver, even at high dosages[101]. 
9.2.4 Applications of Nanodiamonds 
A good drug delivery system requires properties include biocompatibility, dispersability 
and the capability to carry different therapeutics. Also the potential for targets therapy is 
important. Nanodiamonds are able to meet most of these requirements[102-103]. Studies have 
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demonstrated the efficacy and safety of nanodiamonds-mediated delivery in mice[104]. 
Nanodiamond-doxorubicin complexes (ND-Dox) were validated to treat drug-resistant breast 
cancer and liver cancer models. The complexes reduced the capacity of the tumors. 
Meanwhile, the half-time of circulation ND-Dox was 10 times that of unmodified doxorubicin. 
Besides of delivering small molecules, nanodiamonds were investigated to deliver nucleic 
acids when coated with polyethylenimine 800 (PEI 800)[102]. There was a 70-fold increase of 
GFP plasmid transfection efficacy and an increased efficacy over commercial transfection 
reagent when used for siRNA delivery[103]. 
 
 
Figure 9-2: DNA can be electrostatically attached to nanodiamonds by first covering 
negatively charged carboxylated nanodiamonds with positively charged PEI800 
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molecules. A similar electrostatic binding strategy has been used to attach siRNA and 
doxorubicin (Dox) to nanodiamond. 
There are increasing interests in the areas of tissue engineering and regenerative 
medicine. It has been shown that nanodiamond monolayers can be used as a platform for 
neuronal growth[104]. The great mechanical properties, including tunable surface chemistry, 
drug delivery ability, and biocompatibility, make nanodiamond be able to create functional 
tissue engineering scaffolds. One reported application is ND-ODA-PLLA composite. It did not 
affect morphology and proliferation when used for culturing murine 7F2 osteoblast. These 




Figure 9-3: ND–ODA can be used for bio-imaging, as illustrated by this confocal 
micrograph of the fluorescent scaffold made of ND–ODA–PLLA with 7F2 osteoblasts 
grown on it. 
9.3 Methods for Detonation Nanodiamond Administration in A Non-human Primate 
Model 
9.3.1 Non-human Primate Care and Identification 
Cynomolgus monkeys of both genders were used for the study. Their ages ranged from 
three to six years. Three control subjects were used for the study. All the animals were 
maintained by Kunming Biomed International. The control ones were assigned by the 
following numbers: 071691(M), 071837(M), and 071669(M). The test subjects given a 
standard dose of DNDs (15 mg/kg) were assigned identifier numbers 080118(F), 071079(M), 
070473(M), 070476(F), and 080410(F). Test subjects receiving an elevated dose of DNDs (25 
mg/kg) were assigned identifier numbers 071425(M), 071805(M), 070696(F), and 070508(F). 
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Animals were provided with controlled rooms compliant with animal welfare guidelines. 
The environment was maintained as temperature (18-26oC), humidity (30-70%), air 
circulation, and light-dark cycle (12/12 hours). Monkeys were fed with a welfare guideline-
compliant commercial monkey diet. Adverse events were defined as conditions that the 
monkeys displayed any indication of obvious toxicity or intolerance of DNDs. 
9.3.2 Non-human Primate Dosing Protocol 
Each monkey received 6 doses of DNDs at either 15 or 25 mg/kg. Blood and urine 
samples were obtained before each administration and used as the baseline. Three weeks after 
the last administration, blood and urine samples were collected again. The whole treatment 
lasted for duration of six months. 
9.3.3 Non-Human Primate Serum and Urine Analysis 
Serum and urine samples were obtained using conventional equipment and procedures 
that have been previously outlined[105]. Serum chemistry, complete blood count, urinalysis, 
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weight monitoring, and observation period assessment were conducted to comprehensively 
characterize test subject health. 
9.3.4 Non-Human Primate Histopathology Analysis 
Immediately after euthanasia, tissues were harvested and fixed in 10% neutral-buffered 
formalin for at least 48 hours. Then samples were dehydrated in increasing concentrations of 
ethanol and embedded in paraffin wax. Tissues were made into sections that were 4–5 µm thick 
and adhered to positively charged glass slides. Sections were stained with hematoxylin and 
eosin for evaluation. All slides were evaluated using a Nikon Eclipse 80i upright microscope 
(LHS-N100C-1, Nikon Instruments Inc., Japan). 
9.3.5 Statistics 
All analyses were performed in GraphPad Prism using two-way ANOVA using the 
Bonferroni correction for multiple comparisons. A repeated measures analysis was used for the 
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non-human primate studies to take into account between subject variations. Data were 
considered significant at p < 0.05. 
9.4 Results 
9.4.1 Body Weight Analysis after DNDs Administration 
During the period of the study, all the groups were monitored for body weight and 
appetite. No obvious acute or sustained fluctuations in animal body weight were discovered 
during the study period. There were no apparent changes to animal appetite either. These 
results indicated that DNDs administration did not cause severe systemic toxicity or adversely 




Figure 9-4: Weights of monkeys treated with indicated amount of detonation 
nanodiamonds or controls. No significant difference was identified. 
9.4.2 Complete Blood Count Analysis after DNDs Administration 
A complete blood account was regarded as a standard clinical practice. It was used to 
assess the overall health and screen for inflammation, toxicity, and hemolysis and any other 
side effects. Overall, he platelet count (PLT) was the only hematological parameter that had 
statistically significant variation. One week after doses 2, 5, and 6, samples had higher PLT in 
the control group, compared to the other two groups. It should be notice that PLT readings had 
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great fluctuations in all animals. It was more likely that the difference was due to an increase 
in the reads of control group, rather than a decrease in the treatment groups. The values from 
treatment groups were consistent with their baseline before treatment. 
Red blood cell distribution width (RDW-CV, 14.75 ± 1.28%) was assessed and red blood 
cell counts (RBC, 6.22 ± 0.45 × 10
12
/L) were also evaluated as part of the complete blood 
counts. No substantial deviations were investigated in all the test subjects, except the one 
070473, whose RDW-CV reading was elevated compared to its starting and ending levels. It 
was shown negligible fluctuations for Hematocrit (HCT, 48.98 ± 2.94%) levels. Mean 
corpuscular volume (MCV, 78.84 ± 3.34 fL) had higher values at the end of treatment. Mean 
corpuscular hemoglobin (MHC, 22.81 ± 1.11 pg) readings showed very little fluctuation 
within each test subject. And mean corpuscular hemoglobin concentration (MCHC, 289.49 ± 
10.46 g/L) analysis exhibited a generally decreasing trend for all the subjects that converged 




Figure 9-5: Hematologic parameter analysis of monkeys treated with detonation 
nanodiamonds. Monkeys were treated monthly with either a standard dose (15 mg/kg) or 
a high dose (25 mg/kg) of DNDs. Blood was sampled prior to each treatment and 1 week 
after treatment. Statistically significant differences in platelet count were noted at 
multiple time points (*p < 0.05, **p < 0.01). All other parameters were non-significant. 
Taken together, it was demonstrated by these discoveries that the nanoparticle infusions 
did not make the test subjects experience a hemolytic response or be anemic. 
We also measured white blood cell counts (WBC, 13.31 ± 4.41 × 10
9
/L) and neutrophil counts 
(NEU, 6.43 ± 3.72 × 10
9
/L, 46.66 ± 14.37%). Although measurements in all the test subjects 
exhibited substantial fluctuations, we did not find any apparent increasing or depression trends 
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in any of these levels. Large standard deviations were observed with the reference level 
standards for lymphocyte counts (LYM, 6.00 ± 2.38 × 10
9
/L, 45.96 ± 13.20%). We did not 
observe any trends in the values of WBC, NEU, and LYM, while some of them were under the 
expected normal range. 
 
Figure 9-6: Hematologic parameter analysis of monkeys treated with detonation 
nanodiamonds. Monkeys were treated monthly with either a standard dose (15 mg/kg) or 
a high dose (25 mg/kg) of DNDs. Blood was sampled prior to each treatment and 1 week 
after treatment. All other parameters were non-significant. 
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These data provided significant insight about the overall health of the test subjects. No 
trends were observed that were attributable to DND administration, although occasional 
fluctuations were found in marker levels during the study. In addition, all subjects maintained 
their weight during the entire study. The DND administration was demonstrated to be well 
tolerated as there was no clear anemia, inflammatory response, or toxicity. 
9.4.3 Urinalysis Following DND Administration 
We assessed urine from all subjects at the same time points with the hematologic 
analyses. Previous reference studies provided the reference values for urinalysis in 
cynomolgus monkeys. For one time point, urine pH readings showed that subjects 
071079(M/S), 070473(M/S), 080118(F/S), and 071425(M/E) each reached a urine pH level of 
9. However, all of these subjects finished the treatment with normal urine pH values. None of 
these subjects had urinary tract infections, as urine nitrite tests came back negative. Almost all 
test subjects had negative urine glucose (uGLU) readings. One control subject (071691(M)) 
and one treatment subject (070508(F/E)) tested positive for uGLU at one time point each. 
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However, both subjects completed the study with negative uGLU. All subjects had normal 
levels of urobilinogen and were negatively tested for urinary bilirubin, except subject 
071805(M/E). There were two times of positive reading for that subject, but completed with 
negative tests. All subjects were found to have transiently positive urine protein levels 
(uPRO), indicating that protein presence was unlikely due to DND treatment. 
There was at least once during the entire study that tested positive for urine leukocytes 
and erythrocytes (uLEU, uERY) for all subjects. It is usually considered normal for healthy 
subjects when uLEU levels are low. There was no statistically significant difference between 
standard treatment group and control group in the average uLEU levels. Similarly, there were 
no any significant trends for uERY values. 
Finally, substantial variability in all urine electrolytes (sodium, potassium, chloride, and 
calcium) was observed. There were no significant trends in any of these for all groups. 
Furthermore, no evidence of kidney infection or damage was observed during the study. Taken 
together, both the liver and kidneys of all subjects were functioning normally proved by the 
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urinalysis data. In addition, there were no significantly differences in the results between the 
standard and elevated group. 
 
Figure 9-7: Urinalysis of monkeys treated with detonation nanodiamonds. Monkeys were 
treated monthly with either a standard dose (15 mg/kg) or a high dose (25 mg/kg) of 
DNDs. Blood was sampled prior to each treatment and 1 week after treatment. No 
statistically significant variations in parameters were observed. 
9.4.4 Non-human Primate Histopathology Analysis 
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One control (071691(M)), two standard dose monkeys (080118(F) and 071079(M)), and 
two elevated dose monkeys (070696(F) and 071425(M)) were used to conduct tissue analysis. 
Tissue from the lung, heart, liver, kidney, and spleen were stained with hematoxylin and eosin. 
We did not identify any gross abnormality in both the standard and elevated groups compared 
to the controls. Heart sections from elevated group showed increased muscle fiber hypertrophy 
compared to the controls, while there was only mild changes in sections from standard group. 
Evidence of prominent capillary congestion and dilatation compared to the control animals 
was found in the liver parenchyma from the elevated group, while standard ND dose monkeys 
had similar but less advance changes in morphology. Compared to control group, there were 




Figure 9-8: Histologic analysis of monkeys treated with detonation nanodiamonds. 
Monkeys were treated monthly with either a standard dose (15 mg/kg) or a high dose (25 
mg/kg) of DNDs. Tissue samples from the liver, kidney, lung, heart, and spleen were 
obtained at 6 months from control, standard dose (both genders), and elevated dose 
(both genders) for analysis. 
9.5 Conclusion 
This study demonstrated significant insight into the biocompatibility of DND preclinical 
administration in a non-human primate model. The results provided in this study are 
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comprehensive, including DND safety characterization, long study period, and repeated 
dosing scheme. Both genders of cynomolgus monkeys had been evaluated with two DND 
dosing levels, a standard dose of 15 mg/kg (n=5) and an elevated dose of 25 mg/kg (n=4), in 
addition to controls (n=3). This study gave important insight into no apparent adverse effect 
level and maximum tolerated dose of DND administration. The estimated clinical DND 
monotherapy dosage will be between 6.75 and 13.5 mg/kg. Furthermore, combination therapy 
technologies will optimize DND-containing multidrug treatment and further reduce the DND 
and drug dosage. Consequently, both 15 and 25 mg/kg in our study serves as a foundation for 
clinical translation of DND-based therapeutic and contrast agents. Completion of non-human 
primate histology is required to further confirm material tolerance. In addition, to establish in-
human validation protocols, comprehensive pharmacokinetic analysis and the development of 
chemistry, manufacturing, and controls compliance are demanded. 
9.6 Discussion 
The area of nanomedicine has made strides to the improved diagnosis and treatment of 
various diseases, such as cancer and infectious diseases[106-107]. However, progress has been 
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limited as the result of the costs related to drug development. Therefore, in the context of the 
area of drug development, it’s important to select specific carriers, indications, and drugs. 
Among those promising carriers that have been applied in nanomedicine, detonation 
nanodiamonts (DNDs) have recently received increasing attention due to their abilities in 
photostable cell labeling, drug delivery, and medically imaging[109-110], as a result of their 
faceted surfaces and uniform particle structure. In particular, DNDs are able to potently 
binding anthracyclines and sustaining their release with no need for modification either the 
DND surface or the drug itself[111]. These DND-anthracycline complexes are capable of 
improving drug tolerance and maximally efficacious tumor reduction using drug dosages that 
are lethal when delivered on their own. In the area of medically related imaging, DNDs are 
used to carry gadolinium(III) (Gd(III)), leading to a one order of magnitude increase in per- 
G(III) relaxivity for magnetic resonance imaging (MRI) applications[112]. This is among the 
largest increase ever reported for per-gadolinium relaxivity, compared to all nanoparticle and 
clinical MRI contrast agents. 
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To test nanodiamond (ND) biocompatibility, investigators have used different cell lines 
and animal models platforms for several informative studies[111, 113, 114]. These studies were 
largely demonstrated with in vitro, ex vivo, or small animal models. Consequently, to continue 
developing of ND for clinical administration requires the assessment of their tolerance in large 
animal models with comprehensive blood and urine analysis. Furthermore, the implementation 
of a dual gender and long-term large animal study is vital because of the fact that differences 
can exist between male and female subjects. To achieve this goal, we performed our study on 
non-human primate animals, in which male and female cynomolgus monkeys were 
administered an intravenous injection once a month for a period of six months. Two cohorts 
were each administered either a standard (15 mg/kg) or elevated (25 mg/kg) DND dose, while 
blood and urine draws were systematically acquired for comprehensive toxicity analysis. At 
the conclusion of the dosing protocol, the animals were subsequently entered into an 
observation phase to assess visible changes to their health and monitor possible weight 
changes. The results demonstrated that the DNDs were well-tolerated for the duration of non-
human primate animals and also provided important insights as to the maximum tolerated dose 
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(MTD) and the “no observed adverse effect level”. Therefore, these studies provide and 
important foundation for the nonclinical risk assessment of DND-based therapies and imaging 














Full screening results for human Nox2 
miRNA- Fold Change P-value 
106b 0.9000 0.0003 
148b 0.9010 0.0001 
21 0.9049 0.0191 
miR-135b 0.9150 0.0004 
296-5p 0.9155 0.0005 
590-5p 0.9209 0.1019 
33a 0.9233 0.0289 
let-7f-1-3p 0.9250 0.0498 
29c* 0.9258 0.0037 
let-7i 0.9265 0.0268 
204 0.9278 0.0082 
221 0.9315 0.1212 
190 0.9337 0.1169 
miR-7 0.9355 0.0581 
331-3p 0.9362 0.0463 
301a 0.9406 0.0099 
let7a 0.9422 0.1556 
200c* 0.9433 0.1158 
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494 0.9447 0.0159 
491-5p 0.9472 0.0073 
708 0.9477 0.0015 
let-7c 0.9478 0.0461 
542-3p 0.9498 0.0007 
133a 0.9513 0.1503 
331-5p 0.9535 0.0103 
188-5p 0.9536 0.0056 
let-7f 0.9537 0.0355 
29a* 0.9540 0.0792 
124* 0.9540 0.1559 
24 0.9558 0.0815 
216b 0.9562 0.0568 
744-3p 0.9580 0.4949 
16 0.9659 0.1308 
100 0.9615 0.3914 
874 0.9617 0.2782 
499-5p 0.9617 0.0254 
15b 0.9625 0.2871 
125b 0.9625 0.2915 
93* 0.9641 0.0194 
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1 0.9653 0.2942 
miR-144 0.9657 0.1095 
183 0.9657 0.1553 
574-3p 0.9662 0.1014 
196b 0.9683 0.1769 
132 0.9685 0.4838 
137 0.9686 0.0185 
208a 0.9691 0.0077 
27a-5p 0.9691 0.0458 
296-3p 0.9694 0.1267 
431 0.9695 0.4896 
323-3p 0.9702 0.0507 
9 0.9704 0.4396 
361-5p 0.9709 0.4448 
miR-200b 0.9711 0.1925 
184 0.9713 0.1015 
miR-139-5p 0.9720 0.0842 
381 0.9726 0.1005 
223 0.9727 0.3162 
133b 0.9731 0.2680 
188-3p 0.9732 0.0624 
let-7g 0.9733 0.1763 
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127-3p 0.9741 0.2307 
98 0.9742 0.0148 
miR-760 0.9747 0.3794 
342-3P 0.9752 0.3902 
33a* 0.9760 0.4122 
146a 0.9768 0.0637 
425 0.9769 0.0798 
761 0.9770 0.4737 
708* 0.9770 0.0333 
153 0.9775 0.2021 
187 0.9775 0.6121 
551b 0.9779 0.0597 
10a* 0.9780 0.3615 
568 0.9785 0.0693 
504 0.9786 0.3578 
638 0.9789 0.3961 
494 0.9789 0.4309 
744 0.9790 0.1181 
543 0.9792 0.4803 
223 0.9793 0.0184 
455-5p 0.9794 0.0258 
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448 0.9795 0.5576 
183* 0.9796 0.4285 
490-3p 0.9796 0.0792 
377 0.9798 0.4623 
129* 0.9800 0.1372 
181a 0.9803 0.1631 
30a* 0.9813 0.4639 
30a 0.9814 0.1431 
103 0.9817 0.4634 
485-5p 0.9819 0.2796 
484 0.9821 0.3347 
129-5p 0.9825 0.0232 
323-5p 0.9831 0.2398 
652 0.9836 0.0852 
29a 0.9840 0.0149 
1197 0.9841 0.6098 
340-3p 0.9845 0.3283 
93 0.9847 0.1879 
330-5p 0.9849 0.7557 
10b 0.9851 0.4565 
369-5P 0.9857 0.5503 
miR-152 0.9863 0.5410 
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miR-149 0.9876 0.4327 
141 0.9880 0.6568 
324-5P 0.9882 0.5936 
574-5p 0.9884 0.4634 
338-3p 0.9886 0.5254 
154* 0.9888 0.6294 
140-5p 0.9892 0.6354 
181d 0.9896 0.4508 
129-3p 0.9898 0.5787 
423-5P 0.9901 0.7107 
29c 0.9902 0.2705 
34c-5p 0.9907 0.6926 
22-5p 0.9907 0.6013 
miR-200c 0.9910 0.4198 
30c-1* 0.9911 0.7678 
miR-25 0.9917 0.7257 
671-3p 0.9918 0.2629 
210 0.9921 0.8800 
23a 0.9922 0.4062 
20b 0.9923 0.4854 
32 0.9924 0.3872 
98 
138 0.9924 0.5582 
9* 0.9926 0.5981 
365 0.9928 0.7331 
496 0.9929 0.7283 
196a 0.9931 0.8389 
199b-5p 0.9932 0.8278 
128 0.9936 0.7831 
7-1* 0.9936 0.8033 
27b 0.9940 0.5410 
30c-2* 0.9941 0.8232 
154 0.9942 0.8464 
335* 0.9943 0.8297 
411-3p 0.9949 0.7627 
615-5p 0.9949 0.8524 
181c 0.9954 0.8416 
302c 0.9957 0.7313 
miR-192 0.9962 0.7612 
19a 0.9962 0.8113 
122 0.9962 0.9328 
99b* 0.9965 0.8130 
222 0.9967 0.9180 
532-5p 0.9970 0.7646 
  
 99 
191 0.9973 0.9101 
26a 0.9978 0.8145 
142-3p 0.9980 0.8954 
147b 0.9982 0.9504 
759 0.9985 0.9368 
370 0.9990 0.9713 
miR-203 0.9991 0.9662 
410 0.9994 0.9789 
30e 0.9997 0.9848 
423-3p 0.9998 0.9907 
23b 1.0002 0.9774 
195 1.0008 0.9449 
214* 1.0009 0.9570 
26b 1.0014 0.9581 
22 1.0014 0.9011 
29b 1.0022 0.7976 
539 1.0023 0.8486 
miR-10a 1.0024 0.9136 
185 1.0025 0.9727 
99b 1.0026 0.8401 
126 1.0031 0.7665 
100 
194 1.0032 0.9329 
495 1.0035 0.7605 
363 1.0039 0.8851 
214 1.0048 0.9104 
27b* 1.0051 0.8179 
miR-18a 1.0057 0.7484 
379 1.0058 0.8609 
193a-3p 1.0062 0.7570 
99a 1.0063 0.6499 
487a 1.0066 0.8082 
409-3p 1.0068 0.6647 
378 1.0072 0.5615 
433 1.0074 0.6977 
219-5p 1.0076 0.7270 
450a 1.0079 0.7258 
323b-5p 1.0084 0.6692 
miR-367 1.0088 0.5249 
451 1.0091 0.6485 
205 1.0092 0.3560 
101 1.0094 0.8416 
376a 1.0100 0.8133 
486-5p 1.0101 0.7486 
  
 101 
let-7d-3p 1.0103 0.6978 
532-3p 1.0103 0.2611 
20a 1.0107 0.2441 
302d 1.0109 0.4091 
148a 1.0113 0.6905 
302a 1.0116 0.6585 
151-5p 1.0123 0.6524 
124 1.0124 0.4527 
181a* 1.0132 0.5294 
let-7b 1.0141 0.7430 
17 1.0143 0.5803 
let7i-3p 1.0146 0.7406 
653 1.0158 0.4709 
200b* 1.0159 0.6637 
340 1.0179 0.5953 
216a 1.0194 0.3011 
877 1.0195 0.3540 
miR-28-5p 1.0195 0.3572 
150 1.0196 0.1798 
382 1.0202 0.3414 
106b* 1.0205 0.4636 
102 
miR-134 1.0206 0.1047 
557 1.0208 0.2075 
335 1.0214 0.5684 
125a-5p 1.0214 0.4840 
let-7d 1.0218 0.2582 
421 1.0218 0.5686 
208b 1.0226 0.5531 
369-3p 1.0234 0.0512 
let-7b-3p 1.0243 0.1523 
708 1.0246 0.3646 
875-5p 1.0247 0.2305 
148a* 1.0255 0.1098 
let-7e 1.0257 0.4493 
15b* 1.0257 0.3946 
218 1.0268 0.4222 
127-5p 1.0279 0.2546 
663 1.0282 0.5465 
30c 1.0295 0.1836 
186 1.0315 0.0744 
378* 1.0324 0.0350 
130a 1.0331 0.3390 
miR-190b 1.0336 0.1404 
  
 103 
431-3p 1.0338 0.1775 
30d 1.0348 0.1685 
299-5p 1.0361 0.0149 
26b* 1.0362 0.1088 
671-5p 1.0390 0.2123 
107 1.0393 0.0464 
125b-1-3p 1.0396 0.0261 
449a 1.0410 0.0080 
34a 1.0410 0.2661 
30b 1.0436 0.0213 
130b 1.0438 0.2378 
320a 1.0448 0.2536 
20b 1.0456 0.1832 
654-3p 1.0462 0.0345 
140-3p 1.0498 0.2255 
409-5p 1.0522 0.1056 
711 1.0550 0.0640 
146b-5p 1.0553 0.1623 
374b 1.0563 0.0088 
19b 1.0574 0.3611 
338-5p 1.0576 0.0105 
104 
126* 1.0606 0.0714 
92b 1.0660 0.0071 
181b 1.0682 0.0347 
miR-125a-3p 1.0713 0.0114 
378b 1.0720 0.0160 
590-3p 1.0736 0.0524 
218-2* 1.0745 0.3343 
143 1.0844 0.0006 
30e* 1.0850 0.0018 
145 1.0874 0.0764 
199b-3p 1.0886 0.1952 
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